CONTE, Pierfranco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.050
EU - Europa 12.400
AS - Asia 3.708
AF - Africa 25
SA - Sud America 25
Continente sconosciuto - Info sul continente non disponibili 14
OC - Oceania 14
Totale 45.236
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.993
GB - Regno Unito 4.582
IT - Italia 2.293
CN - Cina 1.416
SE - Svezia 1.324
UA - Ucraina 1.044
DE - Germania 953
IE - Irlanda 898
HK - Hong Kong 781
TR - Turchia 682
FI - Finlandia 479
SG - Singapore 463
BG - Bulgaria 380
FR - Francia 155
IN - India 129
BE - Belgio 64
ID - Indonesia 62
RU - Federazione Russa 58
VN - Vietnam 58
CA - Canada 44
IR - Iran 25
MY - Malesia 25
LT - Lituania 24
NL - Olanda 24
JP - Giappone 18
CZ - Repubblica Ceca 16
ES - Italia 16
AU - Australia 14
CH - Svizzera 13
BR - Brasile 12
KR - Corea 12
RO - Romania 12
EU - Europa 10
TW - Taiwan 10
AL - Albania 9
GR - Grecia 9
MX - Messico 8
CL - Cile 7
ET - Etiopia 7
HU - Ungheria 7
PL - Polonia 7
MK - Macedonia 6
AT - Austria 5
EG - Egitto 5
IQ - Iraq 5
BZ - Belize 4
DK - Danimarca 4
KE - Kenya 4
MA - Marocco 4
SI - Slovenia 4
TH - Thailandia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
IL - Israele 3
NO - Norvegia 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
BD - Bangladesh 2
BH - Bahrain 2
BO - Bolivia 2
LY - Libia 2
MD - Moldavia 2
PT - Portogallo 2
RS - Serbia 2
AF - Afghanistan, Repubblica islamica di 1
AN - Antille olandesi 1
AP - ???statistics.table.value.countryCode.AP??? 1
AR - Argentina 1
BY - Bielorussia 1
EC - Ecuador 1
LB - Libano 1
LI - Liechtenstein 1
LV - Lettonia 1
ME - Montenegro 1
MZ - Mozambico 1
NG - Nigeria 1
NP - Nepal 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 45.236
Salva come PNG Salva come JPEG
Città #
Fairfield 4.172
Southend 3.802
Woodbridge 3.069
Houston 2.589
Jacksonville 2.272
Chandler 2.036
Ashburn 1.913
Ann Arbor 1.736
Dearborn 1.571
Seattle 1.514
Wilmington 1.476
Cambridge 1.374
Dublin 896
Nyköping 827
Hong Kong 770
Modena 619
Beijing 546
Princeton 444
San Diego 421
Eugene 379
Sofia 379
Izmir 361
Singapore 308
Des Moines 201
New York 192
Milan 155
Falls Church 142
Helsinki 138
London 132
Boardman 110
Shanghai 104
Rome 96
Norwalk 91
Brussels 62
Bologna 61
Jakarta 59
Hefei 58
Redwood City 57
Dong Ket 54
Fremont 51
Bremen 49
Nanjing 41
Kilburn 38
Kunming 34
Hounslow 33
San Mateo 33
Guangzhou 32
Turin 31
Naples 28
Padova 24
Verona 24
Phoenix 22
Ottawa 21
Vicenza 21
Bari 20
Chiswick 20
Indiana 20
Frankfurt am Main 19
Nanchang 19
Palermo 19
Catania 18
Los Angeles 17
Wuhan 17
Dallas 16
Genoa 16
Fulham 15
Jinan 15
Parma 15
Florence 14
Mountain View 14
Reggio Emilia 14
Tappahannock 14
Toronto 14
Philadelphia 13
San Giuliano Milanese 13
Zhengzhou 13
Chicago 12
Monmouth Junction 12
Piacenza 12
Shenyang 12
Ardabil 11
Bangalore 11
Cagliari 11
Islington 11
Lansdale 11
Leawood 11
Paris 11
Augusta 10
Prescot 10
Ravenna 10
Saint Petersburg 10
Brno 9
Chengdu 9
Hebei 9
Madrid 9
Mumbai 9
Pisa 9
Amsterdam 8
Ferrara 8
Munich 8
Totale 36.266
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 612
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 296
MSC-delivered soluble TRAIl and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma 288
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 280
Rigenerand srl - Spin off Università di Modena e Reggio Emilia 257
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 247
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing 242
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 242
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 240
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 239
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 219
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 217
Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood 217
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 216
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 209
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 209
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici 208
MSC and Tumors: Homing, Differentiation and Secretion Influence The Therapeutic Potentials 207
Mesenchymal progenitors aging highlights a mir-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis 203
Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation 198
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 196
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas 195
Phase I study of intraperitoneal MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with peritoneal carcinosis 194
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 193
Significance of lymph node sampling in epithelial carcinoma of the ovary. 193
Immune characterization of breast cancer metastases: prognostic implications. 193
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer 192
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. 191
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.. 189
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 188
METHOD FOR PRODUCTION OF ANTI-TUMOR TRAIL PROTEIN 185
Achievements and unmet needs in the management of advanced ovarian cancer 185
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. 185
Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. 184
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 183
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 183
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 181
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 181
Timing for starting second line therapy in recurrent ovarian cancer. 179
Prognostic and Predictive Value of Baseline and Posttreatment Molecular Marker Expression in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy 176
A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. 173
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 173
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 171
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 171
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 170
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 170
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. 168
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer 167
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial 166
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 166
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 162
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy 161
Donor Cell-Derived Osteopoiesis Originates from a Self-Renewing Stem Cell with a Limited Regenerative Contribution after Transplantation 161
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. 160
Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. 160
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 158
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 158
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. 158
Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria 157
Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer 155
Gastrointestinal stromal tumor and other primary metachronous and synchronous neoplasms as a suspicious criterion for syndromic setting 154
The sequential use of endocrine treatment for advanced breast cancer: where are we? 154
Triple-negative breast cancer: current management and future options. 154
Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. 152
Primary adrenal gland carcinosarcoma associated with metastatic rectal cancer: a hitherto unreported collision tumor 152
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study 150
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 150
Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. 150
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region. 149
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: A case report 149
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 149
Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas. 148
Cardiotoxicity of Epirubicin/Paclitaxel Containing Regimens: Role of Cardiac Risk Factors 147
Device for cell culture 147
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 147
Paclitaxel and vinorelbine in anthracycline pretreated breast cancer: a phase II study. 146
Neoadjuvant treatment with Single – Agent Cetuximab Followed by 5-Fu, Cetuximab, and Pelvic Radiotherapy: A Phase II Study in Locally Advanced Rectal Cancer. 146
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. 146
Management and treatment of triple-negative breast cancer patients from the NEMESI study: an Italian experience. 146
Biomarkers predicting clinical benefit: fact or fiction? 144
The clinical relevance of endocrine therapy induced changes in lipid metabolism in breast cancer patients 144
Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer. 142
Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A randomized trial of the Gruppo Oncologico Nord Ovest. 141
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 141
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. 141
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). 141
Bevacizumab treatment for advanced breast cancer. 140
Prognostic value of "Dworak" tumor regression grade (TRG) after pre-operative chemo-radiotherapy in rectal cancer (RC) 140
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer 139
Optimizing Bisphosphonate therapy in Oncology 139
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study 139
Tumour kinetics, response to chemotherapy and survival in primary ovarian cancer. 138
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 138
Advanced ovarian cancer in the elderly: Results of consecutive trials with cisplatin-based chemotherapy 138
Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM 138
Dose-finding study and pharmaco-kinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. 137
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. 137
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy 137
In response to Body letter to the editor regarding "Safety of intravenous and oral Bisphosphonates and compliance with dosing regimens" 136
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 136
Totale 17.839
Salva come PNG Salva come JPEG
Categoria #
all - tutte 187.283
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 187.283
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20208.523 0 0 410 708 1.187 1.561 1.598 865 885 272 575 462
2020/20216.646 688 329 691 504 730 397 617 874 264 846 396 310
2021/20226.219 88 931 783 382 147 259 445 325 648 469 962 780
2022/20236.351 741 573 316 510 659 906 77 541 1.521 83 257 167
2023/20243.774 182 248 204 229 705 349 393 705 125 114 163 357
2024/2025521 362 159 0 0 0 0 0 0 0 0 0 0
Totale 45.594